Inactive Instrument

Nutralife Biosciences Inc Stock price Other OTC

Equities

US67091B1044

Pharmaceuticals

Sales 2020 1.26M Sales 2021 627K Capitalization 13.01M
Net income 2020 -2M Net income 2021 -5M EV / Sales 2020 14.5 x
Net Debt 2020 3.16M Net Debt 2021 3.01M EV / Sales 2021 25.6 x
P/E ratio 2020
-4.81 x
P/E ratio 2021
-2.18 x
Employees -
Yield 2020 *
-
Yield 2021
-
Free-Float 54.05%
More Fundamentals * Assessed data
Dynamic Chart
NutraLife BioSciences, Inc. (OTCPK : NLBS) entered into a Stock Exchange Agreement to acquire Healthcare Concierges USA, Inc. from Mrugesh Patel, Pinal Kerai and Aysha Khan for 2 million. CI
NutraLife BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
NutraLife Biosciences, Inc. Executes Master Distribution Agreement with Whole Foods Full Spectrum Processing CI
NutraLife BioSciences, Inc. announced that it has received $0.04 million in funding CI
NutraLife BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Nutralife Biosciences Executes a Joint Venture Agreement With Emergent Health Corporation for the Co-Production, Co-Marketing, and Distribution of Emergent’s Line of Regenerative, and Other Health-Related Nutraceutical, Skincare and Pet Pro CI
NutraLife BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
NutraLife BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
NutraLife BioSciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Nutralife Biosciences Signs Partnership Agreement with Cookies Licensed Retail Products CI
NutraLife BioSciences, Inc. Partners with KOR Medical to Create Cannabinoid-Based Wellness Products CI
NutraLife BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Nutralife Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Nutralife Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Nutralife Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 CI
More news
Managers TitleAgeSince
Founder 52 10-03-31
Chief Operating Officer - 10-03-31
Comptroller/Controller/Auditor - -
Members of the board TitleAgeSince
Founder 52 10-03-31
More insiders
NutraLife BioSciences, Inc. is engaged in the development and distribution of nutritional and dietary oral spray products. The Company is a producer and distributor of nutritional supplements that uses micro molecular formulae and the utilization of an oral spray to provide efficient absorption. Its products are sold to private label distributors who sell the products it manufactures under their own brand name as well as under its own brand name. The Company manufactures and distributes oral spray nutritional and dietary products. Its distribution strategy includes selling to private label customers retailers, distributors, and consumers through retail outlets. Its wholly owned subsidiaries include Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc.
More about the company
  1. Stock
  2. Equities
  3. Stock NutraLife BioSciences, Inc.
  4. Stock Nutralife Biosciences Inc - Other OTC